REFERENCES
- Chilcott J., Tappenden P., Lloyd M., Wight J. P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin. Ther. 2001; 23(11)1792–1823, 10.1016/S0149-2918(00)80078-8
- Diletti E., Hauschke D., Steinijans V. W. Sample size determination for bioequivalence assessment by means of confidence intervals. Int. J. Clin. Pharmacol. Ther. Toxicol. 1991; 29(1)1–8,
- Eckland D. A., Danhof M. Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes 2000; 108(2)234–242, 10.1055/s-2000-8525
- Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int. J. Clin. Pract. Suppl., 121: 19–25, 10.1055/s-2000-8525
- Sripalakit P., Neamhom P., Saraphanchotiwitthaya A. High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. J. Chrom. B 2006; 843(2)164–169, 10.1016/j.jchromb.2006.05.032
- Takeda Pharmaceutical Co. Ltd. Actos® (pioglitazone hydrochloride) full prescribing information. OsakaJapan 2004,
- www.app1.fda.moph.go.th/be/guideline/Thailand/BABE/guideline.doc Thailand Food and Drug Administration. (2001). Guidelines for the conduct of bioavailability and bioequivalence studies. Drug Control Division, Ministry of Public Health, Thailand
- www.springerlink.com/index/V628675G42232436.pdf US Food and Drug Administration. (2000). Guidance for industry: Bioavailability and bioequivalence studies for administered drug products-general considerations. Center for Drug Evaluation and Research, Rockville, MD.
- Waugh J., Keating G. M., Plosker G. L., Easthope S., Robinson D. M. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs 2006; 66(1)85–109,
- Wong H., Ozalp Y., Lainesse A., Alpan R. S. In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. Arzneimittelforschung 2004; 54(9)618–624,
- www.pharmexcil.com/v1/docs/TechSes-I/8 World Health Organization. (2005). Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Quality Assurance and Safety: Medicines, Medicines Policy and Standards, Switzerland